Komori
Shin Nippon Biomedical Laboratories (2395) · RiskRestated

Risks Related to Securing and Disputing Intellectual Property Rights

First written in FY2016. 14 of 15 entries say "Restated". Latest entry: FY2026-H1.

15entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2026-H12016: 120162017: 120172018: 020182019: 120192020: 420202021: 220212022: 220222023: 220232024: 120242025: 12025
Same theme, other companies
Acquisition and validity of the company's intellectual property rights, and risk of infringement lawsuits by third partiesA theme 70 companies write about · 70 as a headwind · 0 as a tailwind

40 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 70 companies compared. The sentences above are computed from all 70.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「No new business or other risks arose during the current interim consolidated accounting period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  2. FY2024-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  3. FY2024-Q2RestatedAnnual report

    「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  4. FY2024-Q1RestatedAnnual report

    「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  5. FY2023-Q2RestatedAnnual report

    「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  6. FY2022-Q3RestatedAnnual report

    「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  7. FY2021RestatedAnnual report

    「しかしながら、当社の研究成果を全て権利化できるという保証はなく、また、保有している特許や将来取得する特許によって当社グループの権利を確実に保全できるという保証もありません。」

    知的財産の権利化不足や第三者との紛争を完全に回避できないリスクを継続している。
  8. FY2021-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  9. FY2021-Q2RestatedAnnual report

    「During the second quarter of the current consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  10. FY2021-Q1RestatedAnnual report

    「During the first quarter of the current consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  11. FY2020RestatedAnnual report

    「有価証券報告書提出日現在、当社グループの開発に関連した特許権等の知的財産権について、第三者との間で訴訟やクレームが発生したという事実はありません。」

    知的財産権の権利化不足・紛争リスクを記載しつつ、提出日現在で第三者との訴訟やクレームはないと説明している。
  12. FY2020-Q3RestatedAnnual report

    「No new business or other risks arose during the nine-month period ended December 31, and there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  13. FY2020-Q2RestatedAnnual report

    「During the second quarter of the current consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    知的財産権の権利化・紛争リスクについて、重要な変更がないと記載している。
  14. FY2017RestatedAnnual report

    「しかしながら、当社の研究成果を全て権利化できるという保証はなく、また、保有している特許や将来取得する特許によって当社グループの権利を確実に保全できるという保証もありません。」

    知的財産の権利化不足や第三者との紛争を完全に回避できないリスクを引き続き記載している。
  15. FY2016First statedAnnual report

    「しかしながら、当社の研究成果を全て権利化できるという保証はなく、また、保有している特許や将来取得する特許によって当社グループの権利を確実に保全できるという保証もありません。」

    弁護士・特許事務所による事前調査を行う一方、第三者との紛争を完全に回避できない可能性を記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Shin Nippon Biomedical Laboratories's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.